Virtici announced today that it has received a three-year, $3.5 million award from the National Institutes of Health (NIH) to support an Institutional Development Award (IDeA) Center of Biomedical Research Excellence.

The Maryland Technology Development Corporation (TEDCO) announced today that six companies, including Virtici spinout Rise Therapeutics, received a total of $800,000 in seed funding. 

Virtici, LLC announced today the spin-out of a new drug development company, Rise Therapeutics, which is focused on developing microbiome-based, immunological therapies. To form the spin-out, Rise obtained key microbiome-related intellectual property and technologies incubated at Virtici to support the development of first-in-class, orally-delivered, biological medicines.

Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced it has closed on $1.8M in Series A financing to support the launch of its new microbiome platform technology.  

Celdara Medical, LLC today announced that it has successfully concluded negotiations with Celyad SA (Euronext Brussels and Paris, and NASDAQ:CYAD) related to their ongoing partnership for discovery and development of CAR T cell therapies.

Today Virtici, Celdara Medical and MBV announced their formation of the first collaborative nationwide network for the development of early stage biotechnologies. The goals are simple: to improve human health by identifying the highest potential innovations in medicine and developing them into the clinic.